Cargando…

The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice

Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150,...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, J, Imai, H, Ohyama, T, Hashimoto, S, Hasunuma, T, Inoue, Y, Kotegawa, T, Ohashi, K, Uemura, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351340/
https://www.ncbi.nlm.nih.gov/pubmed/27197662
http://dx.doi.org/10.1111/cts.12400
_version_ 1782514757804228608
author Luo, J
Imai, H
Ohyama, T
Hashimoto, S
Hasunuma, T
Inoue, Y
Kotegawa, T
Ohashi, K
Uemura, N
author_facet Luo, J
Imai, H
Ohyama, T
Hashimoto, S
Hasunuma, T
Inoue, Y
Kotegawa, T
Ohashi, K
Uemura, N
author_sort Luo, J
collection PubMed
description Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150, 300, and 600 mL) of AJ or water (control). To identify an AJ volume lacking clinically meaningful interaction, we tested a hypothesis that the 90% confidence interval (CI) for geometric mean ratio (GMR) of FEX AUC(AJ)/AUC(water) is contained within a biocomparability bound of 0.5–2.0, with at least one tested volume of AJ. GMR (90% CI) of AUC(AJ 150mL)/AUC(water), AUC(AJ 300mL)/AUC(water), and AUC(AJ 600mL)/AUC(water) were 0.903 (0.752–1.085), 0.593 (0.494–0.712), and 0.385 (0.321–0.462), respectively. While a moderate to large AJ‐FEX interaction is caused by a larger volumes of AJ (e.g., 300 to 600 mL), the effect of a small volume (e.g., 150 mL) appears to be not meaningful.
format Online
Article
Text
id pubmed-5351340
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53513402017-05-23 The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice Luo, J Imai, H Ohyama, T Hashimoto, S Hasunuma, T Inoue, Y Kotegawa, T Ohashi, K Uemura, N Clin Transl Sci Research Pharmacokinetic exposures to fexofenadine (FEX) are reduced by apple juice (AJ); however, the relationship between the AJ volume and the degree of AJ‐FEX interaction has not been understood. In this crossover study, 10 healthy subjects received single doses of FEX 60 mg with different volumes (150, 300, and 600 mL) of AJ or water (control). To identify an AJ volume lacking clinically meaningful interaction, we tested a hypothesis that the 90% confidence interval (CI) for geometric mean ratio (GMR) of FEX AUC(AJ)/AUC(water) is contained within a biocomparability bound of 0.5–2.0, with at least one tested volume of AJ. GMR (90% CI) of AUC(AJ 150mL)/AUC(water), AUC(AJ 300mL)/AUC(water), and AUC(AJ 600mL)/AUC(water) were 0.903 (0.752–1.085), 0.593 (0.494–0.712), and 0.385 (0.321–0.462), respectively. While a moderate to large AJ‐FEX interaction is caused by a larger volumes of AJ (e.g., 300 to 600 mL), the effect of a small volume (e.g., 150 mL) appears to be not meaningful. John Wiley and Sons Inc. 2016-05-19 2016-08 /pmc/articles/PMC5351340/ /pubmed/27197662 http://dx.doi.org/10.1111/cts.12400 Text en © 2016 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research
Luo, J
Imai, H
Ohyama, T
Hashimoto, S
Hasunuma, T
Inoue, Y
Kotegawa, T
Ohashi, K
Uemura, N
The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice
title The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice
title_full The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice
title_fullStr The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice
title_full_unstemmed The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice
title_short The Pharmacokinetic Exposure to Fexofenadine is Volume‐Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice
title_sort pharmacokinetic exposure to fexofenadine is volume‐dependently reduced in healthy subjects following oral administration with apple juice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351340/
https://www.ncbi.nlm.nih.gov/pubmed/27197662
http://dx.doi.org/10.1111/cts.12400
work_keys_str_mv AT luoj thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT imaih thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT ohyamat thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT hashimotos thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT hasunumat thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT inouey thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT kotegawat thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT ohashik thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT uemuran thepharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT luoj pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT imaih pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT ohyamat pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT hashimotos pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT hasunumat pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT inouey pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT kotegawat pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT ohashik pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice
AT uemuran pharmacokineticexposuretofexofenadineisvolumedependentlyreducedinhealthysubjectsfollowingoraladministrationwithapplejuice